Accéder au contenu
Merck

HCN4 mutations in multiple families with bradycardia and left ventricular noncompaction cardiomyopathy.

Journal of the American College of Cardiology (2014-08-26)
Annalisa Milano, Alexa M C Vermeer, Elisabeth M Lodder, Julien Barc, Arie O Verkerk, Alex V Postma, Ivo A C van der Bilt, Marieke J H Baars, Paul L van Haelst, Kadir Caliskan, Yvonne M Hoedemaekers, Solena Le Scouarnec, Richard Redon, Yigal M Pinto, Imke Christiaans, Arthur A Wilde, Connie R Bezzina
RÉSUMÉ

Familial forms of primary sinus bradycardia have sometimes been attributed to mutations in HCN4, SCN5A, and ANK2. In these studies, no structural cardiac alterations were reported in mutation carriers. However, a cluster of reports in the literature describe patients presenting with sinus bradycardia in association with left ventricular noncompaction cardiomyopathy (LVNC), pointing to a shared genetic cause. This study sought to identify the genetic defect underlying the combined clinical presentation of bradycardia and LVNC, hypothesizing that these 2 clinical abnormalities have a common genetic cause. Exome sequencing was carried out in 2 cousins from the index family that were affected by the combined bradycardia-LVNC phenotype; shared variants thus identified were subsequently overlaid with the chromosomal regions shared among 5 affected family members that were identified using single nucleotide polymorphism array analysis. The combined linkage analysis and exome sequencing in the index family identified 11 novel variants shared among the 2 affected cousins. One of these, p.Gly482Arg in HCN4, segregated with the combined bradycardia and LVNC phenotype in the entire family. Subsequent screening of HCN4 in 3 additional families with the same clinical combination of bradycardia and LVNC identified HCN4 mutations in each. In electrophysiological studies, all found HCN4 mutations showed a more negative voltage dependence of activation, consistent with the observed bradycardia. Although mutations in HCN4 have been previously linked to bradycardia, our study provides the first evidence to our knowledge that mutations in this ion channel gene also may be associated with structural abnormalities of the myocardium.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Streptomycin sulfate salt, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Streptomycin sulfate salt, powder, BioXtra, suitable for mouse embryo cell culture
Sigma-Aldrich
Streptomycin sulfate salt, powder
Sigma-Aldrich
Streptomycin Ready Made Solution, 100 mg/mL in water
Streptomycin sulfate, European Pharmacopoeia (EP) Reference Standard
Supelco
Streptomycin solution, ~1 mg/mL in 1 mM EDTA, analytical standard